Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032
Article
PubMed
PubMed Central
CAS
Google Scholar
Solimando AG, Ribatti D, Vacca A, Einsele H (2016) Targeting B-cell non Hodgkin lymphoma: new and old tricks. Leuk Res 42:93–104
Article
PubMed
CAS
Google Scholar
Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184–4190
Article
PubMed
PubMed Central
Google Scholar
van Spriel AB, Puls KL, Sofi M, Pouniotis D, Hochrein H, Orinska Z et al (2004) A regulatory role for CD37 in T cell proliferation. J Immunol 172:2953–2961
Article
PubMed
Google Scholar
Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S et al (2012) Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21:694–708
Article
PubMed
PubMed Central
CAS
Google Scholar
Link MP, Bindl J, Meeker TC, Carswell C, Doss CA, Warnke RA et al (1986) A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol 137:3013–3018
PubMed
CAS
Google Scholar
Schwartz-Albiez R, Dorken B, Hofmann W, Moldenhauer G (1988) The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 140:905–914
PubMed
CAS
Google Scholar
Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M et al (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 19:1376–1383
Article
PubMed
CAS
Google Scholar
Moore K, Cooper SA, Jones DB (1987) Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. J Pathol 152:13–21
Article
PubMed
CAS
Google Scholar
Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R et al (1989) Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7:1027–1038
Article
PubMed
CAS
Google Scholar
Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR et al (1992) Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10:1696–1711
Article
PubMed
CAS
Google Scholar
Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS et al (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110:2569–2577
Article
PubMed
PubMed Central
CAS
Google Scholar
Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E et al (2011) A novel fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118:4159–4168
Article
PubMed
PubMed Central
CAS
Google Scholar
Lambert JM (2013) Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 76:248–262
Article
PubMed
CAS
Google Scholar
Katz J, Janik JE, Younes A (2011) Brentuximab Vedotin (SGN-35). Clin Cancer Res 17:6428–6436
Article
PubMed
CAS
Google Scholar
Lambert JM, Chari RV (2014) Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 57:6949–6964
Article
PubMed
CAS
Google Scholar
Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC et al (2013) A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 122:3500–3510
Article
PubMed
CAS
Google Scholar
Erickson HK, Lambert JM (2012) ADME of antibody-maytansinoid conjugates. AAPS J 14:799–805
Article
PubMed
PubMed Central
CAS
Google Scholar
Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X et al (2014) The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia 28:1501–1510
Article
PubMed
PubMed Central
CAS
Google Scholar
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586
Article
PubMed
Google Scholar
Donaghy H (2016) Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8:659–671
Article
PubMed
PubMed Central
CAS
Google Scholar
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821
Article
PubMed
CAS
Google Scholar
Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I et al (2015) Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 16:704–715
Article
PubMed
CAS
Google Scholar
Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 28:2085–2093
Article
PubMed
CAS
Google Scholar
Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548–558
Article
PubMed
CAS
Google Scholar
Nowakowski GS, Czuczman MS (2015) ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection? Am Soc Clin Oncol Educ Book:e449–e457
Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP et al (2014) A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood 123:1302–1308
Article
PubMed
PubMed Central
CAS
Google Scholar
Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T et al (2014) Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Investig New Drugs 32:1213–1225
Article
CAS
Google Scholar
Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ et al (2015) AGS67E, an anti-CD37 monomethyl Auristatin E antibody-drug conjugate as a potential therapeutic for B/T-cell malignancies and AML: a new role for CD37 in AML. Mol Cancer Ther 14:1650–1660
Article
PubMed
PubMed Central
CAS
Google Scholar
Sawas A, Savage KJ, Perez RP, Advani RH, Melhelm-Bertrandt A, Lackey J et al (2016) A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. J Clin Oncol 34:abstract:7549
Article
Google Scholar